<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192397</url>
  </required_header>
  <id_info>
    <org_study_id>I 44417</org_study_id>
    <secondary_id>NCI-2017-01069</secondary_id>
    <secondary_id>I 44417</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT03192397</nct_id>
  </id_info>
  <brief_title>Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>A Phase II Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well chemotherapy, total body irradiation, and&#xD;
      post-transplant cyclophosphamide work in reducing rates of graft versus host disease in&#xD;
      patients with hematologic malignancies undergoing a donor stem cell transplant. Drugs used in&#xD;
      the chemotherapy, such as fludarabine phosphate and melphalan hydrochloride, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Giving chemotherapy and total-body&#xD;
      irradiation before a donor stem cell transplant helps stop the growth of cells in the bone&#xD;
      marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy&#xD;
      stem cells from a donor are infused into the patient, they may help the patient's bone marrow&#xD;
      make stem cells, red blood cells, white blood cells, and platelets. Sometimes the&#xD;
      transplanted cells from a donor can make an immune response against the body's normal cells&#xD;
      (called graft versus host disease). Giving cyclophosphamide after the transplant may stop&#xD;
      this from happening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the cumulative incidence of extensive chronic graft versus host disease&#xD;
      (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic&#xD;
      regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients&#xD;
      who do not progress before day 100.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate clinical response, engraftment rate, progression-free survival (PFS) at one&#xD;
      year and, overall survival (OS).&#xD;
&#xD;
      II. To determine the cumulative incidence of relapse. III. To evaluate the day 100&#xD;
      transplant-related mortality rate. IV. To determine the cumulative incidence of grade III-IV&#xD;
      acute GVHD.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of melphalan hydrochloride.&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) over 30&#xD;
      minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients&#xD;
      undergo total body irradiation (TBI) on day -1.&#xD;
&#xD;
      STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4,&#xD;
      mycophenolate mofetil IV over 2 hours on days 5-35, and tacrolimus IV and then orally (PO)&#xD;
      once tolerated on days 5-180 with a taper beginning on day 100.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 12 months and then annually&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2017</start_date>
  <completion_date type="Anticipated">August 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extensive chronic graft versus host disease (GVHD)</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>Will be analyzed for each stratum. Will examine in a post-hoc analysis potential chronic GVHD rates of response by human leukocyte antigen (HLA) matching status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response assessed as per bone marrow transplant (BMT) standard of care</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will utilize either straight Kaplan-Meier based estimators or extensions of nonparametric survival models to account for competing risks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade III-IV acute graft versus host disease (GVHD)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will be analyzed in a descriptive fashion with means +/- standard deviations or frequency counts. Will examine in a post-hoc analysis potential chronic GVHD rates of response by human leukocyte antigen (HLA) matching status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will be analyzed in a descriptive fashion with means +/- standard deviations or frequency counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment rate assessed as per bone marrow transplant (BMT) standard of care</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will be analyzed in a descriptive fashion with means +/- standard deviations or frequency counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival assessed as per bone marrow transplant (BMT) standard of care</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will utilize either straight Kaplan-Meier based estimators or extensions of nonparametric survival models to account for competing risks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) assessed as per bone marrow transplant (BMT) standard of care</measure>
    <time_frame>At 1 year</time_frame>
    <description>Will utilize either straight Kaplan-Meier based estimators or extensions of nonparametric survival models to account for competing risks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality rates</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Will be analyzed in a descriptive fashion with means +/- standard deviations or frequency counts.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Complete Remission</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission</condition>
  <condition>Chronic Myelomonocytic Leukemia in Remission</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Minimal Residual Disease</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.&#xD;
STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.&#xD;
GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic hematopoietic stem cell transplant</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>Alkerana</other_name>
    <other_name>Evomela</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Prevention (chemotherapy, TBI, cyclophosphamide)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have a diagnosis of one of the following (one must be yes):&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) (chronic phase intolerant or unresponsive to&#xD;
                  tyrosine kinase inhibitors, accelerated phase, history of blast crisis)&#xD;
&#xD;
               -  Myelodysplastic syndrome (MDS)&#xD;
&#xD;
               -  Myeloproliferative neoplasm (MPN)&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
               -  Non-Hodgkin lymphoma (NHL)&#xD;
&#xD;
               -  Hodgkin lymphoma (HL) (received and failed frontline therapy or failed autologous&#xD;
                  transplantation or inability to collect enough peripheral blood stem cells [PBSC]&#xD;
                  for autologous hematopoietic cell transplant [auto-HCT])&#xD;
&#xD;
               -  Multiple myeloma (MM)&#xD;
&#xD;
               -  Waldenstrom's macroglobulinemia&#xD;
&#xD;
               -  Severe aplastic anemia&#xD;
&#xD;
          -  Histocompatible donor identified:&#xD;
&#xD;
               -  Related donor or unrelated donor matched 5/6 or better (A, B, DRB1)&#xD;
&#xD;
          -  Patients with benign hematological disorders such as severe aplastic anemia do not&#xD;
             have disease requirements. Patients with malignant hematologic disorder must be in CR&#xD;
             (MRD is allowed) with the exception of the following:&#xD;
&#xD;
               -  Patients with MDS/MPN only require &lt;5% myeloblast on bone marrow evaluation.&#xD;
&#xD;
               -  Patients with AML or ALL may be in CRi, patients with MM may be in VGPR&#xD;
&#xD;
          -  Have a Karnofsky performance status score of &gt; 50%&#xD;
&#xD;
          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &gt; 40% predicted, corrected&#xD;
             for hemoglobin and/or alveolar ventilation&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 40%&#xD;
&#xD;
          -  Bilirubin =&lt; 3 x upper limit of normal&#xD;
&#xD;
          -  Liver alkaline phosphatase =&lt; 3 x upper limit of normal&#xD;
&#xD;
          -  Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate&#xD;
             transaminase (SGPT) =&lt; 3 x upper limit of normal&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 40 cc/min by the modified Cockroft-Gault formula&#xD;
&#xD;
          -  Patient must be cleared pre-transplant by Radiation Oncology to be able to receive 400&#xD;
             cGy&#xD;
&#xD;
          -  Participants of child-bearing potential must agree to use adequate contraceptive&#xD;
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry; should a woman become pregnant or suspect she is pregnant while she or her&#xD;
             partner is participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Patients who have failed a prior autologous or allogeneic transplant are eligible;&#xD;
             however, at least 6 months must have elapsed between the start of this reduced&#xD;
             intensity conditioning regimen and the last transplant if patient had a prior&#xD;
             autologous or myeloablative allogeneic bone marrow transplant (BMT)&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy, radiation treatment and/or surgery&#xD;
&#xD;
          -  Participant or legal representative must understand the investigational nature of this&#xD;
             study and sign an Independent Ethics Committee/Institutional Review Board approved&#xD;
             written informed consent form prior to receiving any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bone marrow failure disorders:&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria (PNH)&#xD;
&#xD;
               -  Hereditary bone marrow failure disorders include Diamond-Blackfan anemia,&#xD;
                  Shwachman- Diamond syndrome, Kostmann syndrome, and congenital amegakaryocytic&#xD;
                  thrombocytopenia&#xD;
&#xD;
               -  Other non-malignant hematologic or immunologic disorders that require&#xD;
                  transplantation:&#xD;
&#xD;
                    -  Quantitative or qualitative congenital platelet disorders (including but not&#xD;
                       limited to congenital megakaryocytopenia, absent-radii syndrome, Glanzmann?s&#xD;
                       thrombasthenia)&#xD;
&#xD;
                    -  Quantitative or qualitative congenital neutrophil disorders (including but&#xD;
                       not limited to chronic granulomatous disease, congenital neutropenia)&#xD;
&#xD;
                    -  Congenital primary immunodeficiencies (including but not limited to severe&#xD;
                       combined immunodeficiency syndrome, Wiskott-Aldrich syndrome, CD40 ligand&#xD;
                       deficiency, T-cell deficiencies)&#xD;
&#xD;
                    -  Hemoglobinopathies (including sickle cell disease and thalassemia)&#xD;
&#xD;
          -  Presence of human leukocyte antigen (HLA) antibodies&#xD;
&#xD;
          -  Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)&#xD;
&#xD;
          -  Child-Pugh class B and C liver failure&#xD;
&#xD;
          -  Patients who in the opinion of the treating physician are unlikely to comply with the&#xD;
             restrictions of allogeneic stem cell transplantation based on formal psychosocial&#xD;
             screening. (i.e., serious, uncontrolled psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or&#xD;
             other condition which, in the opinion of treating physician, would make this protocol&#xD;
             unreasonably hazardous for the patient&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Pregnant or nursing female participants&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the Investigator?s opinion deems the participant an unsuitable&#xD;
             candidate to receive study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Ho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roswell Park</last_name>
      <phone>877-275-7724</phone>
      <email>ASKRPCI@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Christine M. Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

